Porcine Deltacoronavirus-like Particles Produced by a Single Recombinant Baculovirus Elicit Virus-Specific Immune Responses in Mice

Design of multi-epitope chimeric phage nanocarrier vaccines for porcine deltacoronavirus

Porcine delta coronavirus (PDCoV) poses a significant threat to the swine industry. Thus, the development of innovative vaccine candidates is critical for PDCoV prevention. This study details the creation of a PDCoV nanoparticle vaccine utilizing bacteriophage (phage) T4 as a delivery platform. B cell and T cell epitopes of the PDCoV spike (S) protein were identified through bioinformatics and assembled into a tandem construct (termed Pep) using a linker. In silico molecular docking revealed stable interactions between Pep and TLR3. Immune stimulation predictions indicated that Pep could trigger a robust immune response. The prokaryotic Pep protein was conjugated with T4 phage to generate the recombinant T4-Pep phage. Experimental data demonstrated that a single T4 phage displayed at least 830 copies of Pep. In a mouse immunoprotection assay, T4-Pep induced significantly higher levels of specific IgG antibodies and superior neutralizing antibody titers against PDCoV compared to the Pep naked peptide antigen. Moreover, T4 phage exhibited potent immunostimulatory effects, with immunized mice showing protection against PDCoV infection. Histological analysis revealed enhanced intestinal mucosal integrity post-immunization. These findings suggest that bacteriophages are promising vectors for the efficient delivery of viral epitopes, offering a potential platform for developing vaccines against porcine enteric coronaviruses.

A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets

Coronaviruses (CoVs) are important pathogens for humans and other vertebrates, causing severe respiratory and intestinal infections that have become a threat to public health because of the potential for interspecies transmission between animals and humans. Therefore, the development of safe, effective vaccines remains a top priority for the control of CoV infection. The unique immunological characteristics of vaccines featuring messenger RNA (mRNA) present an advantageous tool for coronavirus vaccine development. Here, we designed two lipid nanoparticle (LNP)-encapsulated mRNA (mRNA-LNP) vaccines: one encoding full-length spike (S) protein and the other encoding the spike ectodomain (Se) from porcine deltacoronavirus (PDCoV). Fourteen days after primary immunization, both mRNA vaccines induced high levels of immunoglobulin G and neutralizing antibodies in mice, with the S vaccine showing better performance than the Se vaccine. Passive immune protection of the S mRNA vaccine in suckling piglets was confirmed by the induction of robust PDCoV-specific humoral and cellular immune responses. The S mRNA vaccine also showed better protective effects than the inactivated vaccine. Our results suggest that the novel PDCoV-S mRNA-LNP vaccine may have the potential to combat PDCoV infection.

IMPORTANCE

As an emerging porcine enteropathogenic coronavirus, porcine deltacoronavirus (PDCoV) has the potential for cross-species transmission, attracting extensive attention. Messenger RNA (mRNA) vaccines are a promising option for combating emerging and re-emerging infectious diseases, as evidenced by the demonstrated efficacy of the COVID-19 mRNA vaccine. Here, we first demonstrated that PDCoV-S mRNA-lipid nanoparticle (LNP) vaccines could induce potent humoral and cellular immune responses in mice. An evaluation of passive immune protection of S mRNA vaccines in suckling piglets confirmed that the protective effect of mRNA vaccine was better than that of inactivated vaccine. This study suggests that the PDCoV-S mRNA-LNP vaccine may serve as a potential and novel vaccine candidate for combating PDCoV infection.

Prevention and Control of Swine Enteric Coronaviruses in China: A Review of Vaccine Development and Application

Swine enteric coronaviruses (SECs) cause significant economic losses to the pig industry in China. Although many commercialized vaccines against transmissible gastroenteritis virus (TGEV) and porcine epidemic diarrhea virus (PEDV) are available, viruses are still widespread. The recent emergence of porcine deltacoronavirus (PDCoV) and swine acute diarrhea syndrome coronavirus (SADS-CoV), for which no vaccines are available, increases the disease burden. In this review, we first introduced the genomic organization and epidemiology of SECs in China. Then, we discussed the current vaccine development and application in China, aiming to provide suggestions for better prevention and control of SECs in China and other countries.